Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Promising vaccine may provide long-lasting protection against malaria

15.08.2002


Researchers have developed a unique vaccine that destroys a deadly toxin produced by the parasite that causes malaria, which kills more than two million people each year. The vaccine appears extremely promising in animal studies, they say.



If the drug works in humans, it could become a more effective and longer lasting anti-malarial vaccine than those currently available, according to the researchers.

Details of the research will be presented next week (Aug. 21) in Boston at the 224th national meeting of the American Chemical Society, the world’s largest scientific society. The study will be published in the Aug. 15 issue of Nature.


"This research represents an exciting new approach to controlling malaria by blocking the toxin that is responsible for so many deaths," says Peter H. Seeberger, Ph.D., associate professor of chemistry at the Massachusetts Institute of Technology in Cambridge, Mass. "We hope that this is the answer, but we don’t know yet."

Tests of the new vaccine in monkeys are slated to begin soon, while tests on humans could begin within two years, said Seeberger, who is co-leader of the study along with his colleague, Louis Schofield, Ph.D., of the Walter & Eliza Hall Institute of Medical Research in Melbourne, Australia.

Although other vaccines have been developed and tested against malaria, none lasts for more than a few weeks. Most target proteins on the surface of the parasite, which has the ability to change its surface proteins and eventually resist the vaccine, according to Seeberger.

The new vaccine targets the toxin instead of the parasite. Although the parasite itself lives, it is rendered harmless by the destruction of its deadly toxin, he said.

One or two shots of the vaccine are expected to provide lasting protection against the disease. If necessary, its effectiveness could be enhanced by using it in combination with other vaccines that target the malarial parasite, Seeberger said.

Malaria is a life-threatening parasitic disease transmitted by the bite of the female Anopheles mosquito, which transfers deadly one-celled parasites to human blood in an effort to nurture her eggs. The disease can be caused by one of four different parasites. The most lethal is Plasmodium falciparum, which is also responsible for the majority of infections.

Louis Schofield recently discovered that, as part of its life cycle inside its human host, the parasite releases an inflammatory toxin that appears to trigger the fever, convulsions and deaths associated with the disease.

Previous studies by Seeberger’s colleagues demonstrated that small amounts of the toxin — a tiny carbohydrate molecule called GPI — could be used to effectively immunize mice against infection and reduce fatalities. But the human immune system does not recognize such small molecules as foreign and cannot make antibodies to destroy them.

Seeberger and Schofield designed a synthetic version of the toxin and attached it to a protein molecule in hopes that the newly created complex would be large enough for the body to recognize so that an immune response could be launched against it.

When a group of healthy, unvaccinated mice were injected with blood containing a deadly malarial parasite, all died. But when the synthetic toxin was injected into a group of healthy mice and they were subsequently injected with the parasite, 65 to 95 percent survived.

The immunized mice also had enhanced protection from severe inflammatory conditions associated with the disease, including swelling of the brain, the researchers found.

Seeberger and his colleagues are continuing to refine their vaccine formulations to achieve a 100 percent survival rate. They hope that similar results will be seen in people.

According to the World Health Organization (WHO), malaria is one of the major public health problems, along with HIV/AIDS and tuberculosis, in the poorest regions of the world. More than 90 percent of deaths from malaria occur in Africa, mostly among infants and young children. It is estimated that the disease kills one African child every 30 seconds.

More recently, a dramatic surge in the number of malaria cases occurring among U.S. travelers to areas where the disease is common has been reported.


Funding for this research was provided by the National Institutes of Health, the United Nations Development Programme/World Bank/WHO Special Program for Research and Training in Tropical Diseases, the Human Frontiers of Science Program, the Howard Hughes Medical Institute, and the Australian National Health & Medical Research Council.

The paper on this research, CARB 81, will be presented at 9:25 a.m., Wednesday, Aug. 21, at Sheraton Boston, Republic B, during the symposium, "Carbohydrate Immunology and Therapeutics."

Peter H. Seeberger, Ph.D., is an associate professor of chemistry in the department of chemistry at Massachusetts Institute of Technology in Cambridge, Mass.

Louis Schofield, Ph.D., is a researcher at the Walter & Eliza Hall Institute of Medical Research in Melbourne, Australia.


Mark T. Sampson

Beverly Hassell | EurekAlert!
Further information:
http://www.acs.org/

More articles from Health and Medicine:

nachricht 'Living bandages': NUST MISIS scientists develop biocompatible anti-burn nanofibers
16.02.2018 | National University of Science and Technology MISIS

nachricht New process allows tailor-made malaria research
16.02.2018 | Eberhard Karls Universität Tübingen

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Demonstration of a single molecule piezoelectric effect

Breakthrough provides a new concept of the design of molecular motors, sensors and electricity generators at nanoscale

Researchers from the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague), Institute of Physics of the CAS (IP CAS) and Palacký University...

Im Focus: Hybrid optics bring color imaging using ultrathin metalenses into focus

For photographers and scientists, lenses are lifesavers. They reflect and refract light, making possible the imaging systems that drive discovery through the microscope and preserve history through cameras.

But today's glass-based lenses are bulky and resist miniaturization. Next-generation technologies, such as ultrathin cameras or tiny microscopes, require...

Im Focus: Stem cell divisions in the adult brain seen for the first time

Scientists from the University of Zurich have succeeded for the first time in tracking individual stem cells and their neuronal progeny over months within the intact adult brain. This study sheds light on how new neurons are produced throughout life.

The generation of new nerve cells was once thought to taper off at the end of embryonic development. However, recent research has shown that the adult brain...

Im Focus: Interference as a new method for cooling quantum devices

Theoretical physicists propose to use negative interference to control heat flow in quantum devices. Study published in Physical Review Letters

Quantum computer parts are sensitive and need to be cooled to very low temperatures. Their tiny size makes them particularly susceptible to a temperature...

Im Focus: Autonomous 3D scanner supports individual manufacturing processes

Let’s say the armrest is broken in your vintage car. As things stand, you would need a lot of luck and persistence to find the right spare part. But in the world of Industrie 4.0 and production with batch sizes of one, you can simply scan the armrest and print it out. This is made possible by the first ever 3D scanner capable of working autonomously and in real time. The autonomous scanning system will be on display at the Hannover Messe Preview on February 6 and at the Hannover Messe proper from April 23 to 27, 2018 (Hall 6, Booth A30).

Part of the charm of vintage cars is that they stopped making them long ago, so it is special when you do see one out on the roads. If something breaks or...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

2nd International Conference on High Temperature Shape Memory Alloys (HTSMAs)

15.02.2018 | Event News

Aachen DC Grid Summit 2018

13.02.2018 | Event News

How Global Climate Policy Can Learn from the Energy Transition

12.02.2018 | Event News

 
Latest News

Fingerprints of quantum entanglement

16.02.2018 | Information Technology

'Living bandages': NUST MISIS scientists develop biocompatible anti-burn nanofibers

16.02.2018 | Health and Medicine

Hubble sees Neptune's mysterious shrinking storm

16.02.2018 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>